Resources

1 Resources for

micrornas

Subscribe to this listing via:
RSS
Email

BNET Resources

Glaxo Boosts Biotech With Regulus Deal: By Ben Hirschler LONDON (Reuters UK) - GlaxoSmithKline GSK boosted its position in biotech on Thursday by signing a deal that could be worth up to $600 million (303 million pounds) with Regulus Therapeutics, taking it into the hot area of RNA technology. The tie-up covers...; Tags: RNA, Inflammation, Regulus Therapeutics, MicroRNAs, Biotechnology, Alnylam Pharmaceuticals Inc., GlaxoSmithKline Plc., Isis Pharmaceuticals Inc.; News items 2008-04-17

Additional Resources

Invitrogen Scientists Link microRNA Sequences to Cancer Using RNA Samples from BioServe: CARLSBAD, Calif. & BELTSVILLE, Md. -- In research demonstrating that RNA previously thought to have no biological relevance may be of use for therapeutic and diagnostic targets, Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, and BioServe, the leading provider of clinically annotated...; Articles 2008-05-07
Regulus Therapeutics Exclusively Licenses Intellectual Property from Stanford University Relating to microRNA Antagonists to Treat Inflammatory Diseases: CAMBRIDGE, Mass. & CARLSBAD, Calif. -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA miRNA therapeutics, announced today that it has obtained exclusive rights from Stanford University to worldwide patent applications covering methods...; Articles 2008-05-06
Genetic Tool facilitates experimental processes: Designed as single benchtop solution for genetic research, Geniom RT Analyzer[R] provides sample loading, staining, and detection. Analyzer features freely programmable temperature control that optimizes hybridization and enables use of enzymatic reactions directly on microfluidic array for signal enhancement and primer extension assays. It handles broad spectrum of DNA and...; Articles 2008-04-30
Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate: Rosetta Genomics In-Licenses, on a Non-Exclusive Basis, Proprietary MicroRNAs for Research Applications From Rockefeller University Following This Agreement, Rosetta Genomics has Access to a Full Range of Potential MicroRNA Applications Based on These MicroRNAs REHOVOT, Israel and JERSEY CITY, New Jersey, April 28 /PRNewswire-FirstCall/ --...; Articles 2008-04-28

Asuragen Launches The First Validated microRNA Diagnostic Assay: AUSTIN, Texas -- Asuragen, Inc. announced today the launch of the first microRNA miRNA test for clinical diagnosis and disease management. The assay utilizes qRT-PCR technology* and differentiates between chronic pancreatitis and pancreatic cancer pancreatic ductal adenocarcinoma. Pancreatic cancer is the 4th leading cause of cancer related deaths in the...; Articles 2008-04-23
febit to Introduce Geniom RT Analyzer® to U.S. Market at RNAi World Congress: RNA, microRNA Researchers Comprise One of the Main User Groups of febit's Simplified and Automated Microarray Technology MEDFORD, Mass., and HEIDELBERG, Germany, April 22 /PRNewswire/ -- febit holding gmbh today announced it will introduce the Geniom RT AnalyzerR to the U.S. market at RNAi World Congress, which...; Articles 2008-04-22
GlaxoSmithKline and Regulus Therapeutics Form Strategic Alliance To Develop MicroRNA Targeted Therapeutics to Treat Inflammatory Diseases: Companies Announce Significant microRNA Therapeutics Collaboration LONDON & PHILADELPHIA & CARLSBAD, Calif. -- GlaxoSmithKline GSK and Regulus Therapeutics LLC Regulus today announced a worldwide strategic alliance to discover, develop and market novel microRNA-targeted therapeutics to treat inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Regulus is...; Articles 2008-04-17
Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Company's MicroRNA Technology: Tests Will be Developed and Validated Clinically at Clinical Laboratory Improvement Amendments CLIA Certified Laboratory at the University of California, Irvine School of Medicine Rosetta Genomics Expects Three Tests Applying its MicroRNA Technology to be Developed and Offered by CLIA Certified Labs During 2008 REHOVOT, Israel...; Articles 2008-04-14
Marligen Exclusively Licenses Genisphere Labeling Technology for the Detection of micrornas on the xMAP® Platform: Marligen Launches Vantage[TM] Line for the Purification, Labeling and Detection of microRNAs IJAMSVILLE, Md. -- Marligen Biosciences, Inc., a supplier of innovative products for the life sciences research market, will become the exclusive provider of Genisphere's biotinylated labeling kits for detection of microRNAs on the xMAP([R]) multiplex platform....; Articles 2008-04-10
Targeted Genetics Announces Publication of Preclinical Data Supporting the Use of AAV Vectors to Deliver siRNA: Targeted Genetics Corporation (NASDAQ: TGEN)today announced the publication of preclinical data characterizing thenovel use of Adeno-Associated Viral AAV vectors to deliver smallinterfering RNA siRNA for the treatment of Huntington's disease. The goalof this research is to assess the use of interfering RNA to silence themutant huntingtin gene and thus, reduce...; Articles 2008-04-09
Agilent Technologies Expands miRNA Microarray Catalog with New Human, Mouse and Rat Assays: SANTA CLARA, Calif. -- Agilent Technologies Inc. (NYSE:A) today introduced three new microRNA microarray designs: Human miRNA Microarray v2.0, Mouse miRNA Microarray v1.0 and Rat miRNA Microarray v1.0. All are based on the Sanger Institute's miRBase 10.1, updated in December 2007. "Researchers tell us that they value specificity...; Articles 2008-04-09
New MicroRNA Analysis Tools From Applied Biosystems Advance Cancer Research: TaqMan[R] Reagents Speed Workflows and Enable Analysis of Trace Amounts of RNA in Cell and Tumor Samples FOSTER CITY, Calif. -- Research related to a class of non-coding small RNA molecules called microRNAs miRNAs is one of the fastest-growing areas in biomedical research. These molecules have been found...; Articles 2008-04-09
Asuragen Launches Mirna Therapeutics: Asuragen launches Mirna Therapeutics to Develop and Commercialize microRNA Oncology Therapeutics Mirna is Developing "miRNA Replacement" Therapies, Using miRNAs As Drugs to Correct the Down-Regulation Of miRNAs That Occurs in Many Human Cancers AUSTIN, Texas -- Asuragen, Inc. announced today the launch of Mirna Therapeutics, a...; Articles 2008-04-03
Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinical Laboratory Evaluation Program: The Laboratory-Developed Test is Designed to Differentiate Squamous From Non-Squamous Non-Small Cell Lung Cancer NSCLC, Classifying Squamous Cell Carcinoma of the Lung With Sensitivity of 96 Percent and Specificity of 90 Percent. Accurate Diagnosis is Important for Guiding Treatment. Bevacizumab(1), a Therapy for Non-Squamous NSCLC, Includes a Warning...; Articles 2008-04-03
Alnylam Presents Pre-clinical Data from Hypercholesterolemia, Liver Cancer, Ebola, and Progressive Multifocal Leukoencephalopathy Programs at RNAi Keystone Symposium: New Data Highlight Broad Applications of RNAi Therapeutics and Continued Progress in Advancing Pipeline of Innovative Medicines New Results Also Document Significant Advancements in Systemic Delivery of RNAi Therapeutics CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it...; Articles 2008-03-31
Tekmira Pharmaceuticals Presents Data on Improved Drug Delivery Technology at International RNAi Conference: Tekmira Pharmaceuticals Corporation ("Tekmira") (TSX: TKM) announced today that a new second-generation formulation of the Company's liposomal drug delivery technology has the potential to bring a 10-fold increase in potency to RNA interference RNAi drugs that are administered intravenously. The preclinical data are being presented at the "RNAi, MicroRNA, and...; Articles 2008-03-28
Tekmira Pharmaceuticals Presents Data on Improved Drug Delivery Technology at International RNAi Conference.(Conference news): VANCOUVER, BRITISH COLUMBIA, Mar 28, 2008 Marketwire via COMTEX -- Tekmira Pharmaceuticals Corporation ("Tekmira") (TSX:TKM) announced today that a new second-generation formulation of the Company's liposomal drug delivery technology has the potential to bring a 10-fold increase in potency to RNA interference RNAi drugs that...; Articles 2008-03-28
Applied Biosystems Expands Applications for Gene Expression Discovery With Next-Generation Sequencing Platform: New Solution for Small RNA Discovery Enables New Experiments for Understanding Critical Biological and Disease Processes FOSTER CITY, Calif. -- Only in recent years have scientists begun to understand the role of small, non-protein coding RNA molecules in living cells. Breakthroughs in science and technology have revealed that...; Articles 2008-03-27
RxGen and Santaris Pharma Use LNA-antimiR Technology to antagonize the liver-expressed microRNA-122 in Non-Human Primates and to Safely Lower Serum Cholesterol: HAMDEN, Conn. & H0RSHOLM, Denmark -- In a study published in the journal Nature today, Santaris Pharma and RxGen Inc., a specialty pharma services company demonstrated that a systemically delivered Locked Nucleic Acid LNA compound could safely and effectively silence a microRNA target in African green monkeys. The study shows...; Articles 2008-03-27

<< Previous
page 1 of 1
Next >>

Resources

micrornas

BNET Resources

Additional Resources

Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors